Grants and Contracts Details
The investigators at the University of Kentucky will synthesize the opioid ligands designed based on salvinorin A and U50,488. Initially, this will focus on modifying the structure of salvinorin A to minimize efficacy for MAPK (ERK and JNK) signaling while maintaining (or enhancing) efficacy for activation of G i signaling (Specific Aim 1). Work will also be extended modifying the structure of U50,488 (Specific Aim 2). As needed, the investigators at the University of Kansas will purify the synthetic compounds to a high level of purity using spectroscopic techniques.
|Effective start/end date||8/1/19 → 7/31/21|
- The University of Texas Health Science Center at San Antonio: $205,515.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.